The continuous glucose monitoring (CGM) in T2DM has shown tremendous improvement from 2003 to 2024, and this progress continues in 2025. Mader J, presented a session at IDF World Diabetes Congress 2025 from 7th-10th April 2025 in Bangkok. There are 2 types of CGM i.e. Unblinded CGM and Blinded CGM. Unblinded CGM which provides automated alarms and alerts at specific glucose levels and/or changing glucose levels and display glucose values when swiped by a reader/smartphone while blinded CGM do not display glucose to user in real time.
Colagiuri S, presented a session at IDF World Diabetes Congress 2025 from 7th-10th April 2025 in Bangkok. Intermediate hyperglycemia (IH) includes IGT, IFG, and HbA1c. The WHO and ADA criteria for defining IH differ for IFG and the WHO does not have an HbA1c criterion. The 1-h OGTT has been recently advocated as an option. The general target of <7.0% (<53 mmol/mol) should ne personalised, balancing reducing complications, minimising hypoglycemia. HbA1c is important but has not been confirmed as an independent risk factor for complication.
Jaggi S, presented a session at IDF World Diabetes Congress 2025 from 7th-10th April 2025 in Bangkok. CGM has revolutionized the management of diabetes and is now widely acceptable. CGM technology has transformed diabetes care by offering real-time glucose monitoring and trend analysis. Smartphone apps and cloud connectivity enhance CGM data accessibility and clinical decision-making.
In most countries, especially in South Asia, the burden of diabetes and obesity has increased in past few decades. Anjana RM, presented a session at IDF World Diabetes Congress 2025 from 7th-10th April 2025 in Bangkok. In South Asians, type 2 diabetes tends to develop at least 10 years earlier and at significantly lower BMI levels compared to White Europeans.
